Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML)

Joshua F. Zeidner, Matthew C. Foster, Amanda L. Blackford, Mark R. Litzow, Lawrence E. Morris, Stephen A. Strickland, Jeffrey E. Lancet, Prithviraj Bose, M. Yair Levy, Raoul Tibes, Ivana Gojo, Christopher D. Gocke, Gary L. Rosner, Richard F. Little, John J. Wright, L. Austin Doyle, B. Douglas Smith, Judith E. Karp

Research output: Contribution to journalLetter

7 Scopus citations
Original languageEnglish (US)
Pages (from-to)92-95
Number of pages4
JournalLeukemia Research
Volume72
DOIs
StatePublished - Sep 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Zeidner, J. F., Foster, M. C., Blackford, A. L., Litzow, M. R., Morris, L. E., Strickland, S. A., Lancet, J. E., Bose, P., Levy, M. Y., Tibes, R., Gojo, I., Gocke, C. D., Rosner, G. L., Little, R. F., Wright, J. J., Doyle, L. A., Smith, B. D., & Karp, J. E. (2018). Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML). Leukemia Research, 72, 92-95. https://doi.org/10.1016/j.leukres.2018.08.005